Emergent Biosolutions (EBS) 30.61 $EBS
Evolva triggers USD4.0m payment with completion of transfer of EV-035 to Emergent BioSolutions
M2 - Fri Apr 24, 3:18AM CDT
Evolva (SIX: EVE) announced on Thursday the receipt of US government's approval of the transfer (novation) of the GC-072 contract to Emergent BioSolutions Inc (NYSE: EBS).
EBS: 30.61 (-0.22)
Emergent BioSolutions Resumes BioThrax Manufacturing - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 23, 5:12PM CDT
Emergent BioSolutions(EBS) announced that it has completed its internal manufacturing investigation and resumed manufacturing operations of BioThrax.
BIIB: 401.71 (-28.57), EBS: 30.61 (-0.22), HZNP: 31.75 (+0.97), AVEO: 1.92 (-0.08)
Today's Strong And Under The Radar Stock Is Emergent BioSolutions (EBS)
at The Street - Thu Apr 23, 9:30AM CDT
Trade-Ideas LLC identified Emergent BioSolutions (EBS) as a strong and under the radar candidate
EBS: 30.61 (-0.22)
Evolva Completes Transfer of EV-035 to Emergent BioSolutions, Triggering a USD 4 Million Payment
Business Wire - Thu Apr 23, 12:01AM CDT
Evolva (SIX: EVE) today announces the US government's approval of the transfer ("novation"
of the GC-072 contract to Emergent BioSolutions Inc. (NYSE: EBS). This triggers a payment of USD 4 million to Evolva, following an initial upfront payment of USD 1.5 million in December 2014. This does not change the revenue guidance for 2015.
EBS: 30.61 (-0.22)
Emergent BioSolutions Completes Investigation and Resumes BioThrax Manufacturing Activities; Re-Affirms Previous Full-Year 2015 Financial Outlook
GlobeNewswire - Wed Apr 22, 3:01PM CDT
-- Internal investigation completed; implementing targeted corrective and preventive actions
EBS: 30.61 (-0.22)
Monoclonal Antibodies Partnering Deals, Terms and Agreements 2010-2015
M2 - Thu Apr 16, 9:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m7zvsb/monoclonal) has announced the addition of the "Monoclonal Antibodies Partnering Terms and Agreements" report to their offering. The report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors monoclonal antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This report provides details of the latest monoclonal antibody deals announced in the healthcare sectors. This report contains a comprehensive listing of all monoclonal antibody partnering deals announced since 2010 including financial terms where available including over 500 links to online deal records of actual biomarker partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in monoclonal antibody dealmaking Chapter 3 - Leading monoclonal antibody deals Chapter 4 - Big pharma monoclonal antibody deals Chapter 5 - Big biotech monoclonal antibodies deals Chapter 6 - Monoclonal antibody contracts dealmaking directory Chapter 7 - Monoclonal antibody deals by individual technology type Chapter 8 - Monoclonal antibody partnering resource center Companies Mentioned - Partial List - Novo Nordisk - Otsuka - Pfizer - Roche - Sanofi - Servier - Shionogi - Takeda - Teva - Alexion Pharmaceuticals - Elan - Emergent BioSolutions - Galapagos - Genmab - LFB Group - Morphosys - Novo Nordisk - PDL BioPharma - Regeneron Pharmaceuticals - Seattle Genetics - Spectrum Pharmaceuticals - Swedish Orphan Biovitrum - ADMA Biologics - Alexion Pharmaceuticals - Amgen - AstraZeneca - Avecia Biologics - AVEO Pharmaceuticals - Biotest - Boehringer Ingelheim For more information visit http://www.researchandmarkets.com/research/m7zvsb/monoclonal
NVO: 56.65 (+0.44), EBS: 30.61 (-0.22), ADMA: 9.00 (unch), AVEO: 1.92 (-0.08), ALXN: 180.08 (-4.50), AMGN: 167.91 (-1.26), SPPI: 6.10 (+0.07), REGN: 480.09 (+0.01), PDLI: 7.02 (-0.09)
Competitor Analysis: Therapeutic Antibodies 2015 - Biosimilars & Biosuperiors: Featuring 174 Companies
M2 - Thu Apr 09, 6:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4lkr3c/competitor) has announced the addition of the "Competitor Analysis: Therapeutic Antibodies 2015 - Biosimilars & Biosuperiors" report to their offering. This Competitive Intelligence Report about Therapeutic Antibodies 2015: Biosimilars & Biosuperiors provides a competitor evaluation in the field of recombinant monoclonal and polyclonal antibodies in the market, in the pipeline as next generation products and as biosimilar versions as of April 2015. Total sales of recombinant therapeutic monoclonal antibodies originating from companies located in regulated markets reached US$ 82.2 bln ( 8.6% vs previous year) in the year 2014. The report lists specifically for each target the branded products with their 2014 sales and up-side indications in development, as well as biosuperior and biosimilar antibody drug candidates in development. The report includes a compilation of currently active projects in research and development of biosimilar and biosuperior therapeutic antibodies against commercially and clinically validated targets: - VEGF - TNF - Her2 - CD20 - EGF-R - B7.1/B7.2 (CD80/CD86) - IL-6R - Alpha4/beta1/7 integrin - IgE - RSV - RANKL - Complement C5 - IL-12/IL-23 - CD52 Competitor projects are listed in a tabular format providing information on: - Drug Codes - Target / Mechanism of Action - Class of Compound - Company - Product Category - Indication - R&D Stage and additional comments with a hyperlink leading to the source of information Key Topics Covered: 1) 2014 Sales of Therapeutic Antibodies 2) VEGF Antibodies 3) TNF Antibodies 4) Her2 Antibodies 5) CD20 Antibodies 6) EGF-R Antibodies 7) RANKL Antibodies
Complement C5 Antibodies 9) Interleukin-12/-23 Antibodies 10) Alpha4/Beta1/7 Antibodies 11) IgE Antibodies 12) CD80/86 (B7-1/B7-2) Antibodies 13) Interleukin-6 Receptor (IL-6R) Antibodies 14) Respiratory Syncytial Virus (RSV) Antibodies 15) CD52 Antibodies Companies Mentioned: 30 of the 174 Companies Featured - 3SBio - AbbVie - Ablynx - Actavis - ActoGenix - ADC Therapeutics - AET Biotech - Celgene - Celltrion - Ceres Oncology - CIMAB - Clearside Biomedical - Eisai - Eli Lilly - Emergent BioSolutions - Epirus Biopharmaceuticals - Harvest Moon Pharmaceuticals - Hospira - Humabs Biomed - Merck Serono - Merrimack Pharmaceuticals - Mersana Therapeutics - Merus - Reliance Life Sciences - Roche - R-Pharm - RuiYi - Samsung Bioepis (JV of Samsung and Biogen Idec) - Sanofi - Shanghai BioMabs Pharmaceutical For more information visit http://www.researchandmarkets.com/research/4lkr3c/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
MACK: 13.42 (-0.25), BIIB: 401.71 (-28.57), EBS: 30.61 (-0.22), MRK: 57.60 (+0.09), LLY: 71.58 (-0.82), CELGZ: 2.76 (-0.12)
Sezary Syndrome Global Clinical Trials Review, H1, 2015
M2 - Wed Apr 01, 6:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k76vbh/sezary_syndrome) has announced the addition of the "Sezary Syndrome Global Clinical Trials Review, H1, 2015" report to their offering. Sezary Syndrome Global Clinical Trials Review, H1, 2015" provides data on the Sezary Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Sezary Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Sezary Syndrome. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Sezary Syndrome Therapeutics Clinical Trials - Eisai Co., Ltd. - Merck & Co., Inc. - Shionogi & Co., Ltd. - Kirin Holdings Company, Limited - OncoSec Medical Inc. - Janssen Global Services, LLC - Emergent BioSolutions Inc. - arGEN-X BV - Angimmune LLC For more information visit http://www.researchandmarkets.com/research/k7...y_syndrome
EBS: 30.61 (-0.22), MRK: 57.60 (+0.09)
FDA clears Emergent's Anthrasil
Seeking Alpha - at Seeking Alpha - Wed Mar 25, 6:51AM CDT
EBS: 30.61 (-0.22)
Emergent BioSolutions Receives FDA Approval of Anthrasil, Its Anthrax Immune Globulin, for Use in the Treatment of Inhalational Anthrax
GlobeNewswire - Wed Mar 25, 6:00AM CDT
Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved Anthrasil(TM) [Anthrax Immune Globulin Intravenous (Human)], also known as AIGIV, for treatment of inhalational anthrax in combination with appropriate antibacterial drugs. Achievement of this milestone triggers a $7 million payment to the company under a development contract with the Biomedical Advanced Research and Development Authority (BARDA). Anthrasil has received Orphan Drug designation and as a result of this approval, the product qualifies for seven years of market exclusivity.
EBS: 30.61 (-0.22)
Emergent BioSolutions Awarded $31 Million Contract for Advanced Development of NuThrax, a Next Generation Anthrax Vaccine
GlobeNewswire - Tue Mar 24, 6:00AM CDT
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a contract with the Biomedical Advanced Research and Development Authority (BARDA) for the advanced development of NuThrax (anthrax vaccine adsorbed with CPG 7909 adjuvant), also known as AV7909, the company's next generation anthrax vaccine candidate. The contract, valued at $31 million, consists of a 30-month base period of performance to develop NuThrax for post-exposure prophylaxis of anthrax disease. Activities to be completed under the contract include process validation, consistency lot manufacture, assay validation, non-clinical studies, and start-up activities in preparation for the Phase 3 clinical trial.
EBS: 30.61 (-0.22)
Emergent BioSolutions Inks Deals for Its Ebola Vaccine - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 17, 9:40AM CDT
Emergent BioSolutions Inc. announced that it has entered into agreements for its modified vaccinia Ankara Ebola Zaire vaccine candidate.
EBS: 30.61 (-0.22), SRPT: 13.42 (-0.24), TKMR: 18.75 (-0.25), GSK: 46.59 (+0.28)
Emergent Bio makes initial batch of Ebola vaccine for Phase 1 study
Seeking Alpha - at Seeking Alpha - Mon Mar 16, 7:58AM CDT
EBS: 30.61 (-0.22), GSK: 46.59 (+0.28)
Emergent BioSolutions Signs Agreements With Oxford University, GlaxoSmithKline, and NIAID for the Production of an MVA Ebola Zaire Vaccine Candidate
GlobeNewswire - Mon Mar 16, 6:00AM CDT
-- Emergent has completed proof-of concept manufacturing of an MVA Ebola Zaire vaccine candidate anticipated for use in a Phase 1 clinical study in the UK
EBS: 30.61 (-0.22), GSK: 46.59 (+0.28)
Emergent BioSolutions, MorphoSys Start Cancer Drug Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 10, 4:10PM CDT
Emergent BioSolutions Inc. and its partner MorphoSys announced that they have initiated a phase I study on their prostrate cancer candidate, MOR209/ES414.
CYTK: 7.25 (-0.18), EBS: 30.61 (-0.22), HZNP: 31.75 (+0.97), AFFX: 12.44 (-0.16)
Emergent BioSolutions and MorphoSys Initiate Phase 1 Clinical Study to Evaluate the Novel Oncology Immunotherapeutic MOR209/ES414 for Prostate Cancer
GlobeNewswire - Mon Mar 09, 6:00AM CDT
Emergent BioSolutions Inc. (NYSE:EBS) and MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) today announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability, and clinical activity of MOR209/ES414 in patients with metastatic castration-resistant prostate cancer (mCRPC). Under the terms of the companies' co-development and commercialization agreement, achievement of this milestone triggers a payment of US $5 million by MorphoSys to Emergent.
EBS: 30.61 (-0.22)
MorphoSys and Emergent BioSolutions Initiate Phase 1 Clinical Study to Evaluate the Novel Oncology Immunotherapeutic MOR209/ES414 for Prostate Cancer
GlobeNewswire - Mon Mar 09, 1:39AM CDT
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) and Emergent BioSolutions Inc. (NYSE: EBS) today announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability, and clinical activity of MOR209/ES414 in patients with metastatic castration-resistant prostate cancer (mCRPC). Under the terms of the companies' co-development and commercialization agreement, the achievement of this milestone triggers a payment of US $ 5 million by MorphoSys to Emergent.
EBS: 30.61 (-0.22)
Emergent BioSolutions Lags Earnings, Cancels 2015 View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 06, 9:30AM CST
Emergent BioSolutions' (EBS) fourth-quarter earnings of 75 cents per share missed the Zacks Consensus Estimate of 95 cents.
CYTK: 7.25 (-0.18), EBS: 30.61 (-0.22), HZNP: 31.75 (+0.97), AFFX: 12.44 (-0.16)
Emergent Biosolutions Inc's Unexpected Surprise
Brian Orelli, The Motley Fool - Motley Fool - Thu Mar 05, 6:53PM CST
It was supposed to be a fairly unexciting fourth-quarter earnings call for Emergent BioSolutions . Back in January, the biotech preannounced its revenue and income numbers -- in a fairly tight range -- so it could talk about the numbers at the JP...
EBS: 30.61 (-0.22)
Evolva triggers USD4.0m payment with completion of transfer of EV-035 to Emergent BioSolutions
M2 - Fri Apr 24, 3:18AM CDT
Evolva (SIX: EVE) announced on Thursday the receipt of US government's approval of the transfer (novation) of the GC-072 contract to Emergent BioSolutions Inc (NYSE: EBS).
EBS: 30.61 (-0.22)
Emergent BioSolutions Resumes BioThrax Manufacturing - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 23, 5:12PM CDT
Emergent BioSolutions(EBS) announced that it has completed its internal manufacturing investigation and resumed manufacturing operations of BioThrax.
BIIB: 401.71 (-28.57), EBS: 30.61 (-0.22), HZNP: 31.75 (+0.97), AVEO: 1.92 (-0.08)
Today's Strong And Under The Radar Stock Is Emergent BioSolutions (EBS)
at The Street - Thu Apr 23, 9:30AM CDT
Trade-Ideas LLC identified Emergent BioSolutions (EBS) as a strong and under the radar candidate
EBS: 30.61 (-0.22)
Evolva Completes Transfer of EV-035 to Emergent BioSolutions, Triggering a USD 4 Million Payment
Business Wire - Thu Apr 23, 12:01AM CDT
Evolva (SIX: EVE) today announces the US government's approval of the transfer ("novation"
of the GC-072 contract to Emergent BioSolutions Inc. (NYSE: EBS). This triggers a payment of USD 4 million to Evolva, following an initial upfront payment of USD 1.5 million in December 2014. This does not change the revenue guidance for 2015. EBS: 30.61 (-0.22)
Emergent BioSolutions Completes Investigation and Resumes BioThrax Manufacturing Activities; Re-Affirms Previous Full-Year 2015 Financial Outlook
GlobeNewswire - Wed Apr 22, 3:01PM CDT
-- Internal investigation completed; implementing targeted corrective and preventive actions
EBS: 30.61 (-0.22)
Monoclonal Antibodies Partnering Deals, Terms and Agreements 2010-2015
M2 - Thu Apr 16, 9:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m7zvsb/monoclonal) has announced the addition of the "Monoclonal Antibodies Partnering Terms and Agreements" report to their offering. The report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors monoclonal antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This report provides details of the latest monoclonal antibody deals announced in the healthcare sectors. This report contains a comprehensive listing of all monoclonal antibody partnering deals announced since 2010 including financial terms where available including over 500 links to online deal records of actual biomarker partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in monoclonal antibody dealmaking Chapter 3 - Leading monoclonal antibody deals Chapter 4 - Big pharma monoclonal antibody deals Chapter 5 - Big biotech monoclonal antibodies deals Chapter 6 - Monoclonal antibody contracts dealmaking directory Chapter 7 - Monoclonal antibody deals by individual technology type Chapter 8 - Monoclonal antibody partnering resource center Companies Mentioned - Partial List - Novo Nordisk - Otsuka - Pfizer - Roche - Sanofi - Servier - Shionogi - Takeda - Teva - Alexion Pharmaceuticals - Elan - Emergent BioSolutions - Galapagos - Genmab - LFB Group - Morphosys - Novo Nordisk - PDL BioPharma - Regeneron Pharmaceuticals - Seattle Genetics - Spectrum Pharmaceuticals - Swedish Orphan Biovitrum - ADMA Biologics - Alexion Pharmaceuticals - Amgen - AstraZeneca - Avecia Biologics - AVEO Pharmaceuticals - Biotest - Boehringer Ingelheim For more information visit http://www.researchandmarkets.com/research/m7zvsb/monoclonal
NVO: 56.65 (+0.44), EBS: 30.61 (-0.22), ADMA: 9.00 (unch), AVEO: 1.92 (-0.08), ALXN: 180.08 (-4.50), AMGN: 167.91 (-1.26), SPPI: 6.10 (+0.07), REGN: 480.09 (+0.01), PDLI: 7.02 (-0.09)
Competitor Analysis: Therapeutic Antibodies 2015 - Biosimilars & Biosuperiors: Featuring 174 Companies
M2 - Thu Apr 09, 6:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4lkr3c/competitor) has announced the addition of the "Competitor Analysis: Therapeutic Antibodies 2015 - Biosimilars & Biosuperiors" report to their offering. This Competitive Intelligence Report about Therapeutic Antibodies 2015: Biosimilars & Biosuperiors provides a competitor evaluation in the field of recombinant monoclonal and polyclonal antibodies in the market, in the pipeline as next generation products and as biosimilar versions as of April 2015. Total sales of recombinant therapeutic monoclonal antibodies originating from companies located in regulated markets reached US$ 82.2 bln ( 8.6% vs previous year) in the year 2014. The report lists specifically for each target the branded products with their 2014 sales and up-side indications in development, as well as biosuperior and biosimilar antibody drug candidates in development. The report includes a compilation of currently active projects in research and development of biosimilar and biosuperior therapeutic antibodies against commercially and clinically validated targets: - VEGF - TNF - Her2 - CD20 - EGF-R - B7.1/B7.2 (CD80/CD86) - IL-6R - Alpha4/beta1/7 integrin - IgE - RSV - RANKL - Complement C5 - IL-12/IL-23 - CD52 Competitor projects are listed in a tabular format providing information on: - Drug Codes - Target / Mechanism of Action - Class of Compound - Company - Product Category - Indication - R&D Stage and additional comments with a hyperlink leading to the source of information Key Topics Covered: 1) 2014 Sales of Therapeutic Antibodies 2) VEGF Antibodies 3) TNF Antibodies 4) Her2 Antibodies 5) CD20 Antibodies 6) EGF-R Antibodies 7) RANKL Antibodies
Complement C5 Antibodies 9) Interleukin-12/-23 Antibodies 10) Alpha4/Beta1/7 Antibodies 11) IgE Antibodies 12) CD80/86 (B7-1/B7-2) Antibodies 13) Interleukin-6 Receptor (IL-6R) Antibodies 14) Respiratory Syncytial Virus (RSV) Antibodies 15) CD52 Antibodies Companies Mentioned: 30 of the 174 Companies Featured - 3SBio - AbbVie - Ablynx - Actavis - ActoGenix - ADC Therapeutics - AET Biotech - Celgene - Celltrion - Ceres Oncology - CIMAB - Clearside Biomedical - Eisai - Eli Lilly - Emergent BioSolutions - Epirus Biopharmaceuticals - Harvest Moon Pharmaceuticals - Hospira - Humabs Biomed - Merck Serono - Merrimack Pharmaceuticals - Mersana Therapeutics - Merus - Reliance Life Sciences - Roche - R-Pharm - RuiYi - Samsung Bioepis (JV of Samsung and Biogen Idec) - Sanofi - Shanghai BioMabs Pharmaceutical For more information visit http://www.researchandmarkets.com/research/4lkr3c/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. MACK: 13.42 (-0.25), BIIB: 401.71 (-28.57), EBS: 30.61 (-0.22), MRK: 57.60 (+0.09), LLY: 71.58 (-0.82), CELGZ: 2.76 (-0.12)
Sezary Syndrome Global Clinical Trials Review, H1, 2015
M2 - Wed Apr 01, 6:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k76vbh/sezary_syndrome) has announced the addition of the "Sezary Syndrome Global Clinical Trials Review, H1, 2015" report to their offering. Sezary Syndrome Global Clinical Trials Review, H1, 2015" provides data on the Sezary Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Sezary Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Sezary Syndrome. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Sezary Syndrome Therapeutics Clinical Trials - Eisai Co., Ltd. - Merck & Co., Inc. - Shionogi & Co., Ltd. - Kirin Holdings Company, Limited - OncoSec Medical Inc. - Janssen Global Services, LLC - Emergent BioSolutions Inc. - arGEN-X BV - Angimmune LLC For more information visit http://www.researchandmarkets.com/research/k7...y_syndrome
EBS: 30.61 (-0.22), MRK: 57.60 (+0.09)
FDA clears Emergent's Anthrasil
Seeking Alpha - at Seeking Alpha - Wed Mar 25, 6:51AM CDT
EBS: 30.61 (-0.22)
Emergent BioSolutions Receives FDA Approval of Anthrasil, Its Anthrax Immune Globulin, for Use in the Treatment of Inhalational Anthrax
GlobeNewswire - Wed Mar 25, 6:00AM CDT
Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved Anthrasil(TM) [Anthrax Immune Globulin Intravenous (Human)], also known as AIGIV, for treatment of inhalational anthrax in combination with appropriate antibacterial drugs. Achievement of this milestone triggers a $7 million payment to the company under a development contract with the Biomedical Advanced Research and Development Authority (BARDA). Anthrasil has received Orphan Drug designation and as a result of this approval, the product qualifies for seven years of market exclusivity.
EBS: 30.61 (-0.22)
Emergent BioSolutions Awarded $31 Million Contract for Advanced Development of NuThrax, a Next Generation Anthrax Vaccine
GlobeNewswire - Tue Mar 24, 6:00AM CDT
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a contract with the Biomedical Advanced Research and Development Authority (BARDA) for the advanced development of NuThrax (anthrax vaccine adsorbed with CPG 7909 adjuvant), also known as AV7909, the company's next generation anthrax vaccine candidate. The contract, valued at $31 million, consists of a 30-month base period of performance to develop NuThrax for post-exposure prophylaxis of anthrax disease. Activities to be completed under the contract include process validation, consistency lot manufacture, assay validation, non-clinical studies, and start-up activities in preparation for the Phase 3 clinical trial.
EBS: 30.61 (-0.22)
Emergent BioSolutions Inks Deals for Its Ebola Vaccine - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 17, 9:40AM CDT
Emergent BioSolutions Inc. announced that it has entered into agreements for its modified vaccinia Ankara Ebola Zaire vaccine candidate.
EBS: 30.61 (-0.22), SRPT: 13.42 (-0.24), TKMR: 18.75 (-0.25), GSK: 46.59 (+0.28)
Emergent Bio makes initial batch of Ebola vaccine for Phase 1 study
Seeking Alpha - at Seeking Alpha - Mon Mar 16, 7:58AM CDT
EBS: 30.61 (-0.22), GSK: 46.59 (+0.28)
Emergent BioSolutions Signs Agreements With Oxford University, GlaxoSmithKline, and NIAID for the Production of an MVA Ebola Zaire Vaccine Candidate
GlobeNewswire - Mon Mar 16, 6:00AM CDT
-- Emergent has completed proof-of concept manufacturing of an MVA Ebola Zaire vaccine candidate anticipated for use in a Phase 1 clinical study in the UK
EBS: 30.61 (-0.22), GSK: 46.59 (+0.28)
Emergent BioSolutions, MorphoSys Start Cancer Drug Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 10, 4:10PM CDT
Emergent BioSolutions Inc. and its partner MorphoSys announced that they have initiated a phase I study on their prostrate cancer candidate, MOR209/ES414.
CYTK: 7.25 (-0.18), EBS: 30.61 (-0.22), HZNP: 31.75 (+0.97), AFFX: 12.44 (-0.16)
Emergent BioSolutions and MorphoSys Initiate Phase 1 Clinical Study to Evaluate the Novel Oncology Immunotherapeutic MOR209/ES414 for Prostate Cancer
GlobeNewswire - Mon Mar 09, 6:00AM CDT
Emergent BioSolutions Inc. (NYSE:EBS) and MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) today announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability, and clinical activity of MOR209/ES414 in patients with metastatic castration-resistant prostate cancer (mCRPC). Under the terms of the companies' co-development and commercialization agreement, achievement of this milestone triggers a payment of US $5 million by MorphoSys to Emergent.
EBS: 30.61 (-0.22)
MorphoSys and Emergent BioSolutions Initiate Phase 1 Clinical Study to Evaluate the Novel Oncology Immunotherapeutic MOR209/ES414 for Prostate Cancer
GlobeNewswire - Mon Mar 09, 1:39AM CDT
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) and Emergent BioSolutions Inc. (NYSE: EBS) today announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability, and clinical activity of MOR209/ES414 in patients with metastatic castration-resistant prostate cancer (mCRPC). Under the terms of the companies' co-development and commercialization agreement, the achievement of this milestone triggers a payment of US $ 5 million by MorphoSys to Emergent.
EBS: 30.61 (-0.22)
Emergent BioSolutions Lags Earnings, Cancels 2015 View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 06, 9:30AM CST
Emergent BioSolutions' (EBS) fourth-quarter earnings of 75 cents per share missed the Zacks Consensus Estimate of 95 cents.
CYTK: 7.25 (-0.18), EBS: 30.61 (-0.22), HZNP: 31.75 (+0.97), AFFX: 12.44 (-0.16)
Emergent Biosolutions Inc's Unexpected Surprise
Brian Orelli, The Motley Fool - Motley Fool - Thu Mar 05, 6:53PM CST
It was supposed to be a fairly unexciting fourth-quarter earnings call for Emergent BioSolutions . Back in January, the biotech preannounced its revenue and income numbers -- in a fairly tight range -- so it could talk about the numbers at the JP...
EBS: 30.61 (-0.22)
